Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Travis Van Meter

Vascular & Interventional Radiology Dallas, TX Medical Doctor

NPI 1750339461 CMS profile 79758

9101 N Central Expy Ste 550, Dallas, TX 75231

Open in the dashboard

General payments

$32,868

394 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$7,608 paid to institutions, not to them · program year 2019

Through program year 2025, Travis Van Meter of Dallas, TX is reported in the CMS Open Payments database as having received $32,868 across 394 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $7,608 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 88th percentile of Vascular & Interventional Radiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,101 34
2024 General $2,496 54
2023 General $4,349 36
2022 General $7,525 48
2021 General $1,559 48
2020 General $6,911 76
2019 General $8,927 98

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Travis Van Meter
  • Vascular & Interventional Radiology median
  • Middle half of Vascular & Interventional Radiology
  • National median

In program year 2025, general payments to Travis Van Meter were reported at $1,101. Among 3,393 Vascular & Interventional Radiology profiles paid that year, the median was $534 and the middle half received between $166 and $2,075.

Show as a table
Year Travis Van Meter Vascular & Interventional Radiology median Middle half National median
2019 $8,927 $422 $125–$1,555 $163
2020 $6,911 $200 $68–$652 $114
2021 $1,559 $280 $99–$866 $132
2022 $7,525 $433 $137–$1,497 $149
2023 $4,349 $506 $152–$2,019 $160
2024 $2,496 $556 $175–$1,930 $164
2025 $1,101 $534 $166–$2,075 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Sirtex Medical Inc $19,740 185 payments
  2. Boston Scientific Corporation $5,910 69 payments
  3. Embolx, Inc. $1,600 1 payment
  4. Cook Medical LLC $1,071 42 payments
  5. Delcath Systems $786 2 payments
  6. AngioDynamics, Inc. $448 6 payments
  7. Cardiovascular Systems Inc. $439 14 payments
  8. IsoRay, Inc $400 1 payment
  9. Medtronic, Inc. $388 11 payments
  10. Abbott Laboratories $294 12 payments
  11. Other $1,792 51 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $13,626 376 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $12,000 4 payments
  3. Consulting Fee $5,000 3 payments
  4. Travel and Lodging $2,243 11 payments
Products named General payments · program years 2019–2025
  1. SIR-Spheres Microspheres $19,740 185 payments
  2. GENERAL VASCULAR INTERVENTION $3,189 5 payments
  3. GENERAL THERAPIES $1,150 6 payments
  4. Hepzato Kit $786 2 payments
  5. Cook Medical Zilver PTX $676 23 payments
  6. AURYON LASER SYSTEM 100-120 VAC $448 6 payments
  7. Brachytherapy Source $400 1 payment
  8. Diamondback Peripheral Atherectomy Device $301 8 payments
  9. TheraSphere Y90 Glass Microspheres 10 GBq $267 5 payments
  10. Diamondback Peripheral Vascular $225 9 payments
  11. Other $4,854 158 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 8 drugs

Part D claims

371

Median for Diagnostic Radiology: 24

Drug cost

$9,865

Median for Diagnostic Radiology: $190

Branded share of claims

8.6%

Median for Diagnostic Radiology: 0%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xarelto Rivaroxaban Brand 12 $6,473
Ondansetron Hcl Generic 53 $1,077
Sucralfate Generic 56 $799
Methylprednisolone Generic 79 $543
Omeprazole Generic 71 $443
Clopidogrel Clopidogrel Bisulfate Brand 20 $246
Metoclopramide Hcl Generic 62 $194
Ciprofloxacin Hcl Generic 18 $89

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,198 Part D prescribers listed as Diagnostic Radiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 116 billing codes

Paid by Medicare

$1,175,850

Of which drugs: $3,788

Medicare patients

196

Average age 74

Services billed

22,345

104 women, 92 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 52%
Cancer 38%
Diabetes 37%
Ischemic heart disease 32%
Chronic kidney disease 32%
Atrial fibrillation 24%
Depression 24%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml Q9966 Office 51 7,567 $2,182
Injection, propofol, 10 mg J2704 Office 142 9,247 $774
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml Q9967 Office 16 1,457 $136
Injection, cefazolin sodium, 500 mg J0690 Office 45 212 $134
Injection, hydralazine hcl, up to 20 mg J0360 Office 21 28 $100
Injection, vancomycin hcl, 500 mg J3370 Office 28 56 $100
Injection, nitroglycerin, 5 mg J2305 Office 38 76 $82
Injection, ondansetron hydrochloride, per 1 mg J2405 Office 144 992 $72
Injection, hydromorphone, up to 4 mg J1170 Office 13 14 $50
Injection, fentanyl citrate, 0.1 mg J3010 Office 20 23 $16

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Hepzato Kit
  • Delcath Systems $786
$786 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

394 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Vascular & Interventional Radiology in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record